Issues related to prescription drug prices. S.1041 Affordable Prescriptions for Patients Act. Fair Accountability and Innovative Research Drug Pricing Act. S.229 Drug Price Transparency for Consumers Act.
2025 · 1st Quarter (Jan 1 - Mar 31)
CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP)
Filed by WHITMER & WORRALL, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- WHITMER & WORRALL, LLC
- Filing UUID
- f17da13e-8447-49a4-8880-2b2d1a2538bd
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act Patent Eligibility Restoration Act PREVAIL Act S.5573 A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43 Skinny Labels, Big Savings Act S.1040 Drug Competition Enhancement Act
Literal federal measure citations: S. 1041, S. 1097, S. 1096, S.5573, S.43, S.1040
Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.
Literal federal measure citations: S. 1095, S. 1032, H.R. 1843
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.